Most of the studies found correlations between sBTM and bone mineral density (BMD) changes under antiresorptive therapies, although inconsistently. The only published study on the impact of sBTM on persistence
to therapy showed negative results. There was no evidence that sBTM allow the prediction of adverse effects, especially osteonecrosis of the jaw.
Conclusions: sBTM reflect the skeletal effects of anti-osteoporotic treatments. Pretreatment values are not recommended for selecting therapy. Short-term changes are significantly correlated with BMD variation, but there is no published LY3023414 molecular weight evidence that they predict benefit on fracture risk at the individual level. (C) 2011 Elsevier Inc. All rights reserved. Semin Arthritis Rheum 41:157-169″
“BackgroundCurrently, acyclovir (ACV) at 1000mg/day is widely used selleckchem as prophylaxis in the early phase of hematopoietic stem cell transplant (HSCT) in Japan. However, low-dose ACV (200mg/day) has been shown to prevent varicella zoster virus reactivation in the middle and late phases of HSCT.
MethodsTherefore, in this study, we decreased the dose of ACV to 200mg/day in the early phase after HSCT. We analyzed 93 consecutive herpes simplex virus (HSV)-seropositive patients who underwent allogeneic HSCT for the first time in our center between June 2007 and December 2011.
ResultsBefore August 2009,
38 patients received oral ACV at 1000mg/day (ACV1000) until day 35 after
HSCT, whereas 55 patients received oral ACV at 200mg/day (ACV200) after September 2009. We compared the cumulative incidence of HSV infection in the 2 groups. Oral ACV was changed to intravenous administration because of intolerance in 66% and 45% of the patients BAY 63-2521 clinical trial in the ACV1000 and ACV200 groups, respectively (P=0.060). The probability of severe stomatitis (Bearman grade II-III) was 76% and 60% in the ACV1000 and ACV200 groups, respectively (P=0.12). The number of patients who developed HSV disease before day 100 after HSCT was 0 in the ACV1000 group and 2 in the ACV200 group, with a cumulative incidence of 3.6% (P=0.43). HSV disease in the latter 2 patients was limited to the lips and tongue and was successfully treated with ACV or valacyclovir at a treatment dose.
ConclusionACV at 200mg/day appeared to be effective for preventing HSV disease in the early phase after HSCT.”
“Background: Dickkopf-1 (DKK-1), an inhibitor of the Wnt pathway, has recently emerged as an important player in several critical aspects of bone biology.
Methods: We performed an extensive internet search (MEDLINE) using the key words Dickkopf-1 and the abbreviation DICK-1.
Results: DKK-1 is a regulator of bone mass with increased expression linked to osteopenia and decreased expression to high bone mass.